Dewpoint Therapeutics

Dewpoint Therapeutics is an American biotechnology company based in Boston, Massachusetts.

COVID-19

Dewpoint participated as an industry partner in the Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV) public-private partnership hosted by the Foundation for the National Institutes of Health.[1]

Organization

Name Position Notes
Kara Carter Senior Vice President, Discovery Biology ACTIV Preclinical and TRACE Working Groups

Investors

Investors in Dewpoint Therapeutics include:[2][3][4]

  • 3E Bioventures Capital
  • 6 Dimensions Capital
  • Alexandria Venture Investments
  • ARCH Venture Partners
  • Bellco Capital
  • EcoR1 Capital
  • General Catalyst[5]
  • Innovation Endeavors
  • Leaps by Bayer
  • Maverick Ventures
  • Mirae Asset Capital
  • Mubadala Ventures
  • NS Investment
  • Polaris Partners
  • Samsara BioCapital
  • SoftBank Vision Fund[6]

Partners

Dewpoint is developing products through partnerships with:[7]


  1. ACTIV. National Institutes of Health (NIH). Retrieved April 1, 2022, from http://archive.today/2022.01.11-042823/https://www.nih.gov/research-training/medical-research-initiatives/activ ↩︎

  2. Series A - Dewpoint Therapeutics - 2019-01-30 - Crunchbase Funding Round Profile. Crunchbase. Retrieved July 3, 2023, from https://www.crunchbase.com/funding_round/dewpoint-therapeutics-series-a--aac46ca0 ↩︎

  3. Series B - Dewpoint Therapeutics - 2020-09-29 - Crunchbase Funding Round Profile. Crunchbase. Retrieved July 3, 2023, from https://www.crunchbase.com/funding_round/dewpoint-therapeutics-series-b--80fadead ↩︎

  4. Bressi, J., & Peterson, S. (2022, February 3). Dewpoint Therapeutics Announces Completion of $150 Million Series C Financing. Dewpoint Therapeutics. https://web.archive.org/web/20230703183902/https://dewpointx.com/dewpoint-therapeutics-announces-completion-of-150-million-series-c-financing/ ↩︎

  5. All Companies. (2022, October 28). General Catalyst. http://archive.today/2022.12.03-033447/https://www.generalcatalyst.com/list ↩︎

  6. Portfolio. SoftBank Vision Fund. Retrieved May 5, 2023, from https://web.archive.org/web/20230505171511/https://visionfund.com/portfolio ↩︎

  7. Pipeline. Dewpoint Therapeutics. Retrieved July 3, 2023, from http://archive.today/2023.07.03-184111/https://dewpointx.com/pipeline/%23partnerships ↩︎

About the author
Liam Sturgess

Liam Sturgess

Liam Sturgess is a Canadian writer, researcher and investigative reporter focused on issues of human rights and civil liberties, with a particular interest in the COVID-19 pandemic. He is the founder of White Rose Intelligence.

Knowledge is Freedom

Research and intelligence in defense of liberty

White Rose Intelligence

Great! You’ve successfully signed up.

Welcome back! You've successfully signed in.

You've successfully subscribed to White Rose Intelligence.

Success! Check your email for magic link to sign-in.

Success! Your billing info has been updated.

Your billing was not updated.